Skip to Main Content

Wajih Kidwai, MD, FACP

Associate Professor of Clinical Internal Medicine (Medical Oncology); Medical Director, Smilow Cancer Hospital Care Center in Guilford; Medical Director, Smilow Cancer Hospital Care Center in Old Saybrook

Research Summary

I have had the honor and responsibility of working as the Medical Director of our office in Guilford and have maintained my position as it transitioned to Yale Smilow Guilford in 2012. As a result of great patient care development, quality of care and provision of state of the art cancer care here we have been able to expand our services with increased surgical and radiology services and by opening another office in Old Saybrook.

I work in collaboration with Radiation Oncology, which provides excellent service to the patients in our shoreline facility. We have worked together with Radiation Oncology on development of a busy Breast Cancer program with Radiation Oncology, breast surgery and breast radiology.

We have worked together on a number of studies here and are part of Clinical Research Working Group (CRWG) bringing research to the Smilow care centers.

I also attend and contribute to the Institutional Review Board (IRB) for Oncology protocols and have been actively participating since 2012. Having a very busy clinical practice, I usually use the weekend and off-hours to prepare for theses meetings and protocols. I have placed a number of patients on practice changing clinical trials resulting in presentations, papers and abstracts.

I am also honored to represent Yale University/Smilow Cancer Center in the hematopoietic panel of NCCN. I previously was also on the NCCN Panel of Neuroendocrine Tumors.

I have taken an active part in the Yale Quality program and in association with Dr. Anne Chiang and Dr. Kerin Adelson. In November of 2018 I presented our Goals of Care quality project at American Society of Clinical Oncology Palliative Care symposium in San Diego, CA.

I am also working closely with the Survivorship program and Breast cancer related Nutrition and Exercise related trials under the direction of Dr Tara Sanft.

We also are collaborating with Smoking cessation program and Yale palliative care program at the care center.

Extensive Research Description

Clinical trials.... see attached data of Clinical trial/ Investigator/ sub investigator

Clinical Research Working group

IRB oncology Yale University

Coauthors

Research Interests

Breast Neoplasms; Colonic Neoplasms; Lung Neoplasms; Lymphoma; Pancreatic Neoplasms

Selected Publications

  • Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple MyelomaBrowning S, Liu Y, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Syam R, Gorshein E, DiAdamo A, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, Lischuk A, Wei W, Haims A, Neparidze N. Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma Blood 2022, 140: 7308-7310. DOI: 10.1182/blood-2022-166325.
  • Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction TherapyLiu Y, Browning S, VanOudenhove J, Biancon G, Bar N, Parker T, Anderson T, Dhodapkar M, Seropian S, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Montanari F, Lischuk A, Haims A, Wei W, Neparidze N. Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy Blood 2022, 140: 7086-7087. DOI: 10.1182/blood-2022-168109.
  • Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple MyelomaBrowning S, Parker T, Bar N, Anderson T, Dhodapkar M, Seropian S, Lee A, Prebet T, Halene S, Xu M, Gorshein E, Talsania A, Kidwai W, Witt D, Chang V, Lischuk A, Wei W, Haims A, Neparidze N. Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma Blood 2020, 136: 20-22. DOI: 10.1182/blood-2020-136478.
  • Standardizing goals of care (GoC) documentation for new patients with metastatic disease.Kidwai W, Engelking C, Pyle J, Chiang A. Standardizing goals of care (GoC) documentation for new patients with metastatic disease. Journal Of Clinical Oncology 2018, 36: 26-26. DOI: 10.1200/jco.2018.36.34_suppl.26.
  • Endometrial adenocardinoma metastatic to bone diagnosed by fine needle aspiration biopsyAli SZ, Smilari AT, Zaheer W, Brones K. Endometrial adenocardinoma metastatic to bone diagnosed by fine needle aspiration biopsy. Journal of Surgical Pathology 1995, 1:137-141
  • Cervical cancer screening in the elderlyLichtman S, Zaheer W. Cervical cancer screening in the elderly. Primary Care and Cancer 1995, 15:21-22
  • HIV associated malignancy other than Hodgkin's lymphomaLichtman SM, Kaplan M, Zaheer W. HIV associated malignancy other than Hodgkin's lymphoma. Review Cancer (Madrid) 1994, 7(5):141-147
  • Mesenchymoma of liver: care report and review of literatureZaheer W, Allen SL, Ali SZ. Mesenchymoma of liver: care report and review of literature. Annals of Clinical and Laboratory Science 1994, 24(96):495-500

Clinical Trials

ConditionsStudy Title
LungRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
BreastAn Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected With a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
Larynx; Lip, Oral Cavity and PharynxThe BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
ProstateRandomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate Cancer
LungA Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Non-Hodgkin's LymphomaA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
Breast(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Multiple MyelomaNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
PancreasA Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
ProstateSIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer
LungPhase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer
Multiple MyelomaEffective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
BreastA Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
LungIntegration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Colon; RectumPhase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
LungMRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Leukemia, otherA Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
ColonPhase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Other Female Genital; OvaryA Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
LungPhase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer